Dashboard
Manage Tickers

CMPX Compass Therapeutics, Inc.

Nasdaq compasstherapeutics.com


$ 3.90 $ -0.27 (-6.49 %)    

Thursday, 23-Oct-2025 19:47:33 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 613.52 $ 0.00 (0 %)
DIA $ 467.83 $ 0.00 (0 %)
SPY $ 673.66 $ 0.00 (0 %)
TLT $ 91.32 $ 0.00 (0 %)
GLD $ 374.25 $ 0.00 (0 %)
$ 3.89
$ 4.14
$ 3.90 x 500
$ 4.00 x 20
-- - --
$ 1.27 - $ 4.86
1,227,561
na
537.92M
$ 1.22
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-11-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-27-2025 01-01-1970 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-21-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 03-15-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-01-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 03-18-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
18 04-30-2021 03-31-2021 10-Q
19 03-05-2021 12-31-2020 10-K
20 11-09-2020 09-30-2020 10-Q
21 08-13-2020 06-30-2020 10-Q
22 06-08-2020 03-31-2020 10-K
23 02-14-2020 12-31-2019 10-Q
24 11-13-2019 09-30-2019 10-Q
25 08-13-2019 06-30-2019 10-Q
26 07-01-2019 03-31-2019 10-K
27 02-14-2019 12-31-2018 10-Q
28 11-14-2018 09-30-2018 10-Q
29 08-14-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

compass-therapeutics-announces-proposed-public-offering-of-common-stock-size-not-disclosed
Compass Therapeutics Announces Proposed Pu...
08/12/2025 20:05:15

d-boral-capital-maintains-buy-on-compass-therapeutics-maintains-32-price-target
D. Boral Capital Maintains Buy on Compass ...
08/12/2025 12:54:10

D. Boral Capital analyst Jason Kolbert maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $32 price target.

guggenheim-maintains-buy-on-compass-therapeutics-raises-price-target-to-12
Guggenheim Maintains Buy on Compass Therap...
08/12/2025 12:30:49

Guggenheim analyst Michael Schmidt maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and raises the price target from ...

compass-therapeutics-q2-eps-014-misses-012-estimate
Compass Therapeutics Q2 EPS $(0.14) Misses...
08/11/2025 11:03:13

Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate o...

Core News & Articles
Earnings Scheduled For August 11, 2025
08/11/2025 08:32:28

raymond-james-reinstates-outperform-on-compass-therapeutics-announces-9-price-target
Raymond James Reinstates Outperform on Com...
07/01/2025 15:42:50

Raymond James analyst Sean McCutcheon reinstates Compass Therapeutics (NASDAQ:CMPX) with a Outperform and announces $9 price...

compass-therapeutics-q1-eps-012-misses-011-estimate
Compass Therapeutics Q1 EPS $(0.12) Misses...
05/08/2025 12:15:13

Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate o...

d-boral-capital-maintains-buy-on-compass-therapeutics-maintains-32-price-target
D. Boral Capital Maintains Buy on Compass ...
04/28/2025 15:27:51

D. Boral Capital analyst Jason Kolbert maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $32 price target.

compass-therapeutics-announces-its-poster-presentation-entitled-enhanced-efficacy-of-ctx-471-a-cd137-agonist-antibody-in-models-of-immune-checkpoint-failure-via-simultaneous-blockade-of-neo-angiogenesis-american-association-for-cancer-research-annual-meeting-april-2530-2025-in-chicago-illinois
Compass Therapeutics Announces Its Poster ...
04/28/2025 12:06:45

CTX-471 monotherapy demonstrated efficacy in multiple murine models, including models highly resistant to immune checkpoint inh...

guggenheim-reiterates-buy-on-compass-therapeuticsto-buy
Guggenheim Reiterates Buy on Compass Thera...
04/22/2025 13:21:42

Guggenheim analyst Michael Schmidt reiterates Compass Therapeutics (NASDAQ:CMPX) from Buy to Buy.

hc-wainwright--co-reiterates-buy-on-compass-therapeutics-maintains-24-price-target
HC Wainwright & Co. Reiterates Buy on Comp...
04/21/2025 17:35:13

HC Wainwright & Co. analyst Joseph Pantginis reiterates Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $24 ...

d-boral-capital-maintains-buy-on-compass-therapeutics-maintains-32-price-target
D. Boral Capital Maintains Buy on Compass ...
04/21/2025 12:20:18

D. Boral Capital analyst Jason Kolbert maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $32 price target.

compass-therapeutics-doses-first-patient-in-investigator-sponsored-trial-of-tovecimig-for-patients-with-biliary-tract-cancer
Compass Therapeutics Doses First Patient I...
04/21/2025 12:03:52

hc-wainwright--co-maintains-buy-on-compass-therapeutics-raises-price-target-to-24
HC Wainwright & Co. Maintains Buy on Compa...
04/04/2025 10:40:05

HC Wainwright & Co. analyst Joseph Pantginis maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and raises the pric...

guggenheim-reiterates-buy-on-compass-therapeutics-maintains-12-price-target
Guggenheim Reiterates Buy on Compass Thera...
04/02/2025 15:37:13

Guggenheim analyst Michael Schmidt reiterates Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $12 price target.

leerink-partners-upgrades-compass-therapeutics-to-outperform-raises-price-target-to-6
Leerink Partners Upgrades Compass Therapeu...
04/02/2025 12:04:37

Leerink Partners analyst Andrew Berens upgrades Compass Therapeutics (NASDAQ:CMPX) from Market Perform to Outperform and rai...

small-cap-compass-therapeutics-shares-positive-primary-goal-data-from-pivotal-cancer-drug-study-for-biliary-tract-cancer
Small Cap Compass Therapeutics Shares Posi...
04/01/2025 18:00:12

Compass Therapeutics' Phase 2/3 trial shows tovecimig plus paclitaxel significantly improves response rates in advanced bil...

d-boral-capital-maintains-buy-on-compass-therapeutics-maintains-32-price-target
D. Boral Capital Maintains Buy on Compass ...
04/01/2025 11:25:53

D. Boral Capital analyst Jason Kolbert maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $32 price target.

compass-therapeutics-announced-statistically-significant-top-line-data-on-the-primary-efficacy-endpoint-for-companion-002-the-companys-ongoing-phase-23-trial-of-tovecimig-formerly-ctx-009-in-combination-with-paclitaxel-in-patients-with-advanced-biliary-tract-cancer
Compass Therapeutics Announced Statistical...
04/01/2025 11:07:05

Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), in...

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
03/31/2025 21:05:46

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION